SOW
PTGX icon

State of Wyoming’s Protagonist Therapeutics PTGX Stock Holding History

State of Wyoming’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,070
Closed -$181K – 1987
2025
Q4 		$181K Buy
+2,070
New +$169K 0.02% 1045
2025
Q3 		– Sell
-3,985
Closed -$220K – 2013
2025
Q2 		$220K Buy
3,985
+2,528
+174% +$121K 0.03% 847
2025
Q1 		$70.5K Sell
1,457
-6,375
-81% -$267K 0.01% 1320
2024
Q4 		$302K Buy
7,832
+832
+12% +$36.3K 0.04% 554
2024
Q3 		$315K Buy
7,000
+5,509
+369% +$223K 0.05% 399
2024
Q2 		$51.7K Buy
+1,491
New +$43.7K 0.01% 1310
2021
Q4 		– Sell
-26
Closed – – 1954
2021
Q3 		$0 Sell
26
-95
-79% -$4.05K ﹤0.01% 1314
2021
Q2 		$5K Buy
121
+64
+112% +$2.11K ﹤0.01% 1077
2021
Q1 		$1K Buy
+57
New +$1.44K ﹤0.01% 495

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

State of Wyoming's PTGX Position: Q1 2026 in Review

State of Wyoming sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 2,070 shares — an estimated $181K sold.

State of Wyoming first reported a position in PTGX in Q1 2021 and held it in 9 quarters. The position peaked at $315K in Q3 2024. 318 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • State of Wyoming reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • State of Wyoming sold 2,070 Protagonist Therapeutics shares in Q1 2026, an estimated $181K.
  • State of Wyoming first reported a position in Protagonist Therapeutics in Q1 2021 and held it in 9 quarters.
  • State of Wyoming's Protagonist Therapeutics position peaked at $315K in Q3 2024.
  • 318 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on State of Wyoming's 13F filing for Q1 2026, filed 13 May 2026.